Results 71 to 80 of about 35,575 (190)

Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity, Co‐Alterations and Outcomes

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Background Biliary tract cancers (BTCs) represent distinct biological and genomic entities. Anatomic and geographic heterogeneity in genomic profiling of BTC subtypes, genomic co‐alterations, and their impact on long‐term outcomes are not well defined.
Diamantis I. Tsilimigras   +3 more
wiley   +1 more source

Association of ulcerative colitis, celiac disease, primary sclerosing cholangitis and liver cirrhosis in a young male

open access: yesJGH Open, 2023
Inflammatory bowel diseases (IBD), including ulcerative colitis, are chronic autoimmune conditions characterized by inflammation of the digestive system.
Ahmad N. Alkhaledi   +5 more
doaj   +1 more source

Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. [PDF]

open access: yes, 2017
BACKGROUND: Primary sclerosing cholangitis is a chronic cholestatic liver disease that is associated with both hepatobiliary and colorectal malignancies, which can result in liver cirrhosis and its complications. The optimal pharmacological treatment for
Davidson, Brian R   +6 more
core   +4 more sources

Circulating let‐7 Predicts Hepatic Fibrogenesis of 12‐Month Post‐Nucleos(t)ide Analog Treatment in Patients With Hepatitis B Virus

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Chronic hepatitis B virus (HBV) infection is associated with potential complications of liver cirrhosis and hepatocellular carcinoma. To date, there are no effective and noninvasive clinical markers that can predict the risk of liver fibrosis early and accurately in chronic hepatitis B (CHB) patients treated with nucleos(t)ide analogs (NAs ...
Yi‐Shan Tsai   +16 more
wiley   +1 more source

Primary sclerosing cholangitis: a pre-malignant condition [PDF]

open access: yes, 2017
Primary sclerosing cholangitis (PSC) is a chronic, progressive, cholestatic liver disease with no known cure. It is a serious condition, and diagnosis comes with an increased risk of developing cancer of the gallbladder, bile ducts or liver. Symptoms can
Mortimore, Gerri
core   +2 more sources

IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis

open access: yesGut and Liver, 2019
Sclerosing cholangitis (SC) is defined as a condition with progressive stenosis and destruction of the bile ducts due to diffuse inflammation and fibrosis and currently includes three categories: primary sclerosing cholangitis (PSC), secondary ...
Atsushi Tanaka
doaj   +1 more source

Survival after liver transplantation in the United Kingdom and Ireland compared with the United States

open access: yes, 2007
<b>Background and Aim</b>: Surgical mortality in the US is widely perceived to be superior to that in the UK. However, previous comparisons of surgical outcome in the two countries have often failed to take sufficient account of case-mix or ...
Copley, L.P.   +4 more
core   +2 more sources

Controversies in the management of primary sclerosing cholangitis [PDF]

open access: yes, 2016
Primary sclerosing cholangitis (PSC) remains a rare but significant disease, which affects mainly young males in association with inflammatory bowel disease.
Devlin, J   +4 more
core   +1 more source

AUTOIMMUNE LIVER DAMAGE IN PATIENT WITH LYELL`S SYNDROME

open access: yesMedicina v Kuzbasse, 2019
Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) are independent liver diseases. But in some cases, patients have syndromes of several liver disease.
Елена Анатольевна Талицкая   +3 more
doaj  

Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease?

open access: yesJournal of Translational Autoimmunity, 2021
Takayasu arteritis and primary sclerosing cholangitis are two rare disorders. The pathogenesis of Takayasu arteritis involves immune-mediated mechanisms, and corticosteroids represent the mainstay for treatment.
Giacomo Mulinacci   +4 more
doaj  

Home - About - Disclaimer - Privacy